Other substances

XG014

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

XG014 is a human monoclonal antibody identified in a memory B cell clone from a convalescent COVID-19 individual with high serum IgG neutralizing activity against SARS-CoV-2. The antibody has a high neutralizing capability (IC50 of 5.1 ng/mL) and also cross-neutralizes SARS-CoV. XG014 does not induce antibody-dependent enhancement. Experimentally, the antibody was resistant to most of point mutations in RBD (Zhou et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD Spike protein In vitro Antibody	Huh-7 cells (pseudovirus-based assay); SARS-CoV-2 pseudovirus; SARS-CoV pseudovirus; SARS-CoV-2 strain nCoV-SH01 (GenBank: MT121215.1)	8.11	The antibody has a high neutralizing capability (IC50 of 5.1 ng/mL) and also cross-neutralizes SARS-CoV. XG014 does not induce antibody-dependent enhancement. Experimentally, the antibody was resistant to most of point mutations in RBD.	Jan/12/2021

AI-suggested references

Link	Publication date
An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope	Sep/23/2021

Export (.csv)